famitinib + HS-10296

**famitinib + HS-10296** is a combination regimen under clinical investigation for the treatment of **EGFR-mutant non-small cell lung cancer (NSCLC)**. - **HS-10296 (almonertinib)** is a third-generation, orally available, small molecule **EGFR tyrosine kinase inhibitor** that selectively inhibits both EGFR-sensitizing mutations and the T790M resistance mutation, sparing wild-type EGFR. - **Famitinib** is a multi-targeted tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor (c-Kit), exerting antiangiogenic and antitumor effects. - The combination demonstrates **synergistic antitumor activity** by enhancing inhibition of EGFR-mediated downstream signaling (AKT and ERK pathways) and angiogenesis, leading to increased tumor cell apoptosis and reduced tumor proliferation and migration in preclinical models. - Developed for advanced and metastatic EGFR-mutant NSCLC, particularly in patients who have progressed after prior EGFR TKI therapy.

Brand names

almonertinib

Other names

famitinib + almonertinibfamitinib + HS-10296